Upstream Bio, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Upstream Bio, Inc. (Nasdaq: UPB) is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders. Founded in 2021 and headquartered in Waltham, Massachusetts, the company advances verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), a cytokine driving pro-inflammatory signaling upstream of multiple immune-mediated cascades; verekitug, a novel recombinant fully human immunoglobulin G1 monoclonal antibody, potently inhibits the TSLP receptor and has demonstrated rapid, substantial, and sustained inhibition for up to 24 weeks in clinical trials, including reductions in fractional exhaled nitric oxide and blood eosinophils in asthma patients. The company conducts global Phase 2 placebo-controlled trials evaluating verekitug across chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD), with positive top-line data from the CRSwNP trial (VIBRANT) reported in 2025 meeting primary and secondary endpoints at Week 24 for the 100 mg dose every 12 weeks. Recent developments include completion of enrollment in the severe asthma Phase 2 trial (VALIANT) in June 2025 with top-line data expected in Q1 2026, initiation of the COPD Phase 2 trial (VENTURE) in July 2025 dosing the first patient, an initial public offering in October 2024 raising $293 million to fund operations through 2027, and institutional investment such as FMR LLC's acquisition of a significant stake in November 2024. Upstream Bio operates primarily in the United States, targeting patients underserved by current standards of care including inhaled therapies and emerging biologics in the respiratory sector.
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Upstream Bio to Participate in Upcoming March Investor Conferences
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Consensus PT from Brokerages
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Average Price Target from Brokerages
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study